Compare USCB & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USCB | TTRX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.1M | 298.8M |
| IPO Year | 2021 | 2025 |
| Metric | USCB | TTRX |
|---|---|---|
| Price | $23.12 | $13.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $23.00 | $8.00 |
| AVG Volume (30 Days) | 55.4K | ★ 69.8K |
| Earning Date | 04-23-2026 | 05-31-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 7.26 | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.46 | N/A |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.36 | $2.57 |
| 52 Week High | $23.89 | $14.39 |
| Indicator | USCB | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 72.88 |
| Support Level | $21.92 | $9.02 |
| Resistance Level | $23.81 | N/A |
| Average True Range (ATR) | 0.58 | 1.04 |
| MACD | 0.00 | 0.37 |
| Stochastic Oscillator | 57.66 | 83.21 |
USCB Financial Holdings Inc is a bank holding company. Through its banking subsidiary, it offers relationship-based banking products, services, and solutions to a diverse set of clients in the local markets it operates in and international clients with U.S. banking needs. The Group's products and services offerings mainly include traditional deposit products, including commercial and consumer checking accounts, money market deposit accounts, savings accounts, etc.; e-banking services; title insurance policies for real estate transactions; and a variety of lending products such as small business loans, commercial real estate loans, business credit cards, etc.; and others. Geographically, its primary banking market is South Florida.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.